RedHill Biopharma Ltd. Initiates Phase III Study of RHB-105 for H. pylori Infection

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL-AVIV, Israel, Oct. 30, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that it has initiated the patient screening process in the ERADICATE Hp study - a Phase III clinical study in the U.S. designed to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed Helicobacter pylori (H. pylori) bacterial infection. Initiation of the RHB-105 Phase III clinical study follows the necessary approvals including FDA acceptance of the Company's Investigational New Drug (IND) application and Institutional Review Board (IRB) approval.

Help employers find you! Check out all the jobs and post your resume.

Back to news